By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Small Interference RNAs (siRNAs). According to news reporting originating from Caen, France, by NewsRx correspondents, research stated, "Cartilage healing by tissue engineering is an alternative strategy to reconstitute functional tissue after trauma or age-related degeneration. However, chondrocytes, the major player in cartilage homeostasis, do not self-regenerate efficiently and lose their phenotype during osteoarthritis."
Our news editors obtained a quote from the research from the University of Caen, "This process is called dedifferentiation and also occurs during the first expansion step of autologous chondrocyte implantation (ACI). To ensure successful ACI therapy, chondrocytes must be differentiated and capable of synthesizing hyaline cartilage matrix molecules. We therefore developed a safe procedure for redifferentiating human chondrocytes by combining appropriate physicochemical factors: hypoxic conditions, collagen scaffolds, chondrogenic factors (bone morphogenetic protein-2 [BMP-2], and insulin-like growth factor I [IGF-I]) and RNA interference targeting the COL1A1 gene. Redifferentiation of dedifferentiated chondrocytes was evaluated using gene/protein analyses to identify the chondrocyte phenotypic profile. In our conditions, under BMP-2 treatment, redifferentiated and metabolically active chondrocytes synthesized a hyaline-like cartilage matrix characterized by type IIB collagen and aggrecan molecules without any sign of hypertrophy or osteogenesis. In contrast, IGF-I increased both specific and noncharacteristic markers (collagens I and X) of chondrocytes. The specific increase in COL2A1 gene expression observed in the BMP-2 treatment was shown to involve the specific enhancer region of COL2A1 that binds the trans-activators Sox9/L-Sox5/Sox6 and Sp1, which are associated with a decrease in the trans-inhibitors of COL2A1, c-Krox, and p65 subunit of NF-kappaB."
According to the news editors, the research concluded: "Our procedure in which BMP-2 treatment under hypoxia is associated with a COL1A1 siRNA, significantly increased the differentiation index of chondrocytes, and should offer the opportunity to develop new ACI-based therapies in humans."
For more information on this research see: Enhanced hyaline cartilage matrix synthesis in collagen sponge scaffolds by using siRNA to stabilize chondrocytes phenotype cultured with bone morphogenetic protein-2 under hypoxia. Tissue Engineering Part C, Methods, 2013;19(7):550-67 (see also Small Interference RNAs (siRNAs)).
The news editors report that additional information may be obtained by contacting F. Legendre, Laboratoire Microenvironnement Cellulaire et Pathologies, MILPAT, EA 4652, SFR ICORE 146, Universite de Caen Basse-Normandie, UFR de Medecine, Caen, France. Additional authors for this research include D. Ollitrault, M. Hervieu, C. Bauge, L. Maneix, D. Goux, H. Chajra, F. Mallein-Gerin, K. Boumediene, P. Galera and M. Demoor.
Keywords for this news article include: Caen, Tissue Engineering, Biomedical Engineering, Biomedicine, France, Europe, Collagen, Peptides, Treatment, Bone Research, Bioengineering, Bone Morphogenetic Protein 2, Extracellular Matrix Proteins, TGF beta Superfamily Proteins, Small Interference RNAs (siRNAs).
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC